Formycon and Bioeq say resubmission of the biologics license application for their ranibizumab candidate will not affect launch timing in US or European markets.
In an update on development of a ranibizumab biosimilar candidate, FYB201, for the treatment of macular degeneration, Formycon said it is hoping the FDA will grant approval for large-scale commercialization of the agent and that the approval process will be simplified.
In February, Formycon and its licensing partner, Bioeq, said the FDA had requested additional information related to a manufacturing change and that it would require resubmission of the application for FYB201. A piece of equipment was shifted to a new location, and the change was unrelated to product quality or other product characteristics, Formycon and Bioeq said.
The processing equipment had been moved based on the request of European health authorities, and because of this, the FDA requested additional manufacturing data to support the biologics license application (BLA). The BLA was withdrawn while these data were generated.
The companies are aiming at the market for the Lucentis reference product. Lucentis is a Roche product and garnered sales of $1.12 billion in the third quarter of 2020, down 14% from the year-ago comparable quarter.
In the update, Formycon and Bioeq said they had adjusted their resubmission strategy for FYB201 and intended to file the application with the FDA sometime in the first half of 2021. They said the delay was not expected to have any effect on timing for the launch for FYB201 in the United States or European Union.
Ranibizumab is used to treat wet age-related macular degeneration, a disease that causes excessive formation of blood vessels in the retina of the eye, resulting in a progressive loss of central vision, severe visual impairment, or blindness.
Ranibizumab is also used in the treatment of diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization, and macular edema following retinal vein occlusion.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.